Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 07:16pm CEST

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, [email protected]

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
06/18LIZ BARRETT, NOVARTIS : ‘My personal mission is to help find cures for can..
AQ
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/16PFIZER : WHO approves Ghana trachoma free
AQ
06/16PFIZER : The New York Academy of Medicine Honors Dr. Freda Lewis-Hall, Dr. Ruth ..
AQ
06/15ViiV Healthcare`s two-drug HIV regimen successful in late-stage studies; Glax..
AQ
06/15PFIZER : John Witzig Named to NBAA Board of Directors
AQ
06/15NOVO NORDISK A/S : Keynote Speakers Announced for 2018 Annual Meeting & Expo
AQ
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
AQ
06/14PFIZER : New Findings from Pfizer in the Area of Algorithms Reported (Time Serie..
AQ
06/14PFIZER : Study Data from Pfizer Provide New Insights into Macular Edema (A CCR2/..
AQ
More news
News from SeekingAlpha
06/18Jane's May Dividend Income Tracker - Retirement Accounts 
06/18Aptinyx Proposes Final Terms For $80 Million IPO 
06/18FDA accepts Myriad Genetics' application for BRACAnalysis CDx as companion di.. 
06/18DIVIDEND PORTFOLIO REVIEW : New Dividend Record 
06/14ViiV Healthcare's two-drug HIV regimen successful in late-stage studies; Glax.. 
Financials ($)
Sales 2018 54 381 M
EBIT 2018 20 780 M
Net income 2018 12 874 M
Debt 2018 21 840 M
Yield 2018 3,78%
P/E ratio 2018 16,63
P/E ratio 2019 15,05
EV / Sales 2018 4,31x
EV / Sales 2019 4,12x
Capitalization 213 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,9 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER0.39%212 690
JOHNSON & JOHNSON-12.25%328 858
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880
AMGEN6.39%122 422